Top Markets
#1 Akedo Akedo +62.21%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.61%
#4 Cross Cross +42.54%
#5 Black Phoenix Black Phoenix +34.09%
#6 Velvet Velvet +30.86%
#7 OVERTAKE OVERTAKE +24.86%
#8 Cap Cap +16.59%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +14.42%
#10 Bitway Bitway +12.57%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Tiaan Consumer Ltd. Tiaan Consumer Ltd.

Tiaan Consumer Ltd.

TIAANC
Rank in Stocks #38854
Tiaan Consumer Ltd. specializes in the production and distribution of ayurvedic... Tiaan Consumer Ltd. specializes in the production and distribution of ayurvedic and herbal items. The enterprise was founded on March 27, 1992, and its main corporate offices are situated in Mumbai, India.
Share Price
$0.06930531
Last synced: 2026-05-25
Market Cap
$773.91K
Change (1 day)
0.00%
Change (1 year)
-11.41%
Country
IN
Trade Tiaan Consumer Ltd. (TIAANC)

Category

Healthcare
Revenue for Tiaan Consumer Ltd. (TIAANC)
Revenue in Aug 2026 TTM: 0
According to Tiaan Consumer Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Tiaan Consumer Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.54B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $830.81M -
US